Zanzalintinib: all 47 studies that test it
Page 1 of 1. Open to participants first (42), then studies with results posted, then the rest; newest registration first within each.
- Study of Tegavivint Plus Zanzalintinib in Patients With Advanced Hepatocellular CarcinomaNot yet recruitingNCT07878689Phase 1/2
- Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)Not yet recruitingNCT07845786Phase 2
- Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid TumorsNot yet recruitingNCT07773454Phase 1
- Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual DiseaseRecruitingNCT07750158Phase 3
- Zanzalintinib in Unresectable and Progressive MPGGsNot yet recruitingNCT07714551Phase 2
- A Phase 2 Multicenter Single-Arm Clinical Trial of Zanzalintinib and Pembrolizumab in Subjects With Resectable Clear Cell Renal Cell CarcinomaNot yet recruitingNCT07691476Phase 2
- Study to Evaluate the Efficacy of Zanzalintinib in the Treatment of Relapsed or Metastatic Adenoid Cystic Carcinomas of the Head and NeckNot yet recruitingNCT07682675Phase 2
- NIMBLE-CRC: NeoImmunoModulation Before Leveraging Excision in Colorectal Rectal CancerNot yet recruitingNCT07677579Phase 2
- Zanzalintinib Efficacy Post Pluvicto® in Chemotherapy Naïve Metastatic Castration Resistant Prostate CancerNot yet recruitingNCT07623460Phase 2
- Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyEnrolling by invitationNCT07620574Phase 3
- Phase II Trial of Zanzalitinib in Patients With Metastatic Castration Resistant Prostate CancerNot yet recruitingNCT07608718Phase 2
- Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on ImmunotherapyNot yet recruitingNCT07578025Phase 2
- A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory NeuroblastomaNot yet recruitingNCT07527169Phase 2
- Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular CarcinomaNot yet recruitingNCT07511504Phase 2
- A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)RecruitingNCT07489495Phase 3
- H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC)Not yet recruitingNCT07484139Phase 2
- Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid CancerNot yet recruitingNCT07470489Phase 2
- A Study of Zanzalintinib in Participants With Recurrent or Progressive MeningiomaRecruitingNCT07428616Phase 2
- Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue SarcomaRecruitingNCT07283731Phase 2
- A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)RecruitingNCT07227402Phase 3
- Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular CancerNot yet recruitingNCT07226063Phase 2
- Zanzalintinib in Men With Aggressive Variant Prostate CancerRecruitingNCT07218666Phase 2
- A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)RecruitingNCT07193550Phase 2
- Zanzalintinib for Advanced Urothelial Carcinoma Progressing After Prior TherapyNot yet recruitingNCT07185945Phase 2
- Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)RecruitingNCT07049926Phase 1/2
- Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone MetastasesRecruitingNCT07043608Phase 2
- Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver CancerRecruitingNCT07042919Phase 1/2
- Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)RecruitingNCT06962332Phase 1
- XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid CancerRecruitingNCT06959641Phase 2
- Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before SurgeryRecruitingNCT06959511Phase 2
- Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and LeiomyosarcomaRecruitingNCT06957431Phase 1
- A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid TumorsRecruitingNCT06952010Phase 1
- Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine TumorsRecruitingNCT06943755Phase 2/3
- Maintenance Zanzalintinib With Etoposide After HDCT in GCTRecruitingNCT06937866Phase 1/2
- Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)RecruitingNCT06926634Phase 2
- Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCCRecruitingNCT06912087Phase 1
- XL092 and Cemiplimab in BRAF WT Thyroid CancerRecruitingNCT06902376Phase 1
- Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine CancerRecruitingNCT06795009Phase 1
- Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable MetastasisRecruitingNCT06794229Phase 2
- Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)RecruitingNCT06698250Phase 2
- XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue SarcomaRecruitingNCT06571734Phase 2
- XL092 in Patients With Metastatic Castration-Resistant Prostate CancerRecruitingNCT06568562Phase 2
- A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)TerminatedNCT03337698Phase 1/2Results posted
- Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue SarcomaSuspendedNCT06968988Phase 1
- Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT06082167Phase 2/3
- Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell CarcinomaActive, not recruitingNCT05678673Phase 3
- Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal CancerActive, not recruitingNCT05425940Phase 3